A Phase 1, Repeat Dose Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection in Japanese Subjects with Advanced Hepatic Fibrosis (METAVIR F3-4)

Trial Profile

A Phase 1, Repeat Dose Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection in Japanese Subjects with Advanced Hepatic Fibrosis (METAVIR F3-4)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs ND L02 s0201 (Primary)
  • Indications Hepatic fibrosis
  • Focus Adverse reactions
  • Acronyms METAVIR F3-4
  • Sponsors Nitto Denko
  • Most Recent Events

    • 16 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 Apr 2017 Planned End Date changed from 30 Apr 2017 to 31 Dec 2017.
    • 12 Jul 2016 Planned End Date changed from 31 Aug 2016 to 30 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top